Search Results
Your search for ASCO matches 21875 pages
Showing 17801 - 17850MEK Inhibitor Improves Outcomes in Metastatic Uveal Melanoma
For the first time, a drug has proven effective in the treatment of uveal (ocular) melanoma that has metastasized, according to a randomized multicenter phase II study presented at the 2013 ASCO Annual Meeting.1 “This study is the first to demonstrate an improved clinical outcome with any systemic...
ASCO President Clifford Hudis, MD, on the 2013 ASCO Annual Meeting
This year’s ASCO Annual Meeting was really exciting in two specific ways. First, we saw the development of high-tech novel therapies and combinations that effectively manipulate the immune system and extend survival in historically difficult-to-treat diseases, like metastatic melanoma (eg,...
Expert Point of View: Ezra Cohen, MD
“These patients finally have options,” commented the DECISION trial’s discussant at the ASCO Plenary Session, Ezra Cohen, MD, Associate Professor of Medicine and Associate Director for Education at the University of Chicago Comprehensive Cancer Center. He further noted that differentiated thyroid...
Sorafenib Halts Disease Progression in Metastatic Differentiated Thyroid Cancer
For the first time in decades, a drug has halted disease progression in treatment-resistant differentiated thyroid cancer, according to the results of a phase III study presented at the 2013 ASCO Annual Meeting.1 No new drugs have been approved for differentiated thyroid cancer in 40 years, but...
Simple Rapid Vinegar Test Cuts Cervical Cancer Death Rates by One-third in Rural India
In the era of personalized medicine for cancer care, it was both surprising and encouraging to hear about a simple low-tech intervention delivered by women in the community that cut the rate of death from cervical cancer in India by about one-third. The intervention, a simple visual inspection...
Practice-changing Study Shows Survival Benefit for Antiangiogenesis in Advanced Cervical Cancer
The addition of bevacizumab (Avastin) to chemotherapy prolongs overall survival in women with metastatic cervical cancer compared with chemotherapy alone, according to the results of a randomized phase III study presented at the Plenary Session of the ASCO Annual Meeting.1 Women on the...
It’s Déjà Vu All Over Again
Yogi Berra offered the comment “It’s déjà vu all over again” when he witnessed Mickey Mantle and Roger Maris repeatedly hitting back-to-back home runs in the early 1960s. His pithy remark neatly summarizes my reaction when I read the article, “Dose-Adjusted EPOCH-Rituximab Therapy in Primary...
GM-CSF Boosts Survival Benefit of Ipilimumab in Metastatic Melanoma
For metastatic melanoma, the activity of ipilimumab can be boosted by the addition of granulocyte-macrophage colony-stimulating factor (GM-CSF, Leukine), according to a phase II study that found the combination improved overall survival, vs ipilimumab alone. The results were presented at the 2013...
MSKCC Community Mourns the Death of Trudy Nan Small, MD
Trudy Nan Small, MD, was a pediatric hematologist at Memorial Sloan-Kettering Cancer Center who specialized in the diagnosis and care of children undergoing hematopoietic stem cell transplantation for hematologic malignancies and those with life-threatening genetic disorders of the immune system....
Erratum
In the June 10 issue of The ASCO Post, the article, “Study Questions Routine Use of Imaging after Treatment for Diffuse Large B-cell Lymphoma,” includes an error in an Expert Point of View box featuring an interview with Andrew D. Zelenetz, MD, PhD. Dr. Zelenetz is quoted as saying that at his...
Shiitake Mushroom
The use of dietary supplements by patients with cancer has increased significantly over the past 2 decades despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and...
SIDEBAR: Expect Questions about Programmed Death Receptors
In today’s high-tech, sci-fi–loving culture, “programmed death receptor” seems like a term apt to stir up public interest, particularly when those receptors are being “targeted” by “agents.” In this case, however, the agents are antibodies that target programmed death 1 (PD-1) receptor and disable...
'Spectacular' Results with Immunotherapies in Melanoma Galvanize the Oncology Community
In the News focuses on media reports that your patients may have questions about at their next visit. This continuing column will provide summaries of articles in the popular press that may prompt such questions, as well as comments from colleagues in the field. Much of the news about immunotherapy ...
Focus on the Society of Rhode Island Clinical Oncologists
Founded in 1994, just 1 year after ASCO launched the State/Regional Affiliate Program, the Society of Rhode Island Clinical Oncologists is one of ASCO’s oldest state affiliates. Like many other ASCO affiliates, the Providence-based group is facing a myriad of challenges, including ensuring...
SIDEBAR: Big Ten Cancer Research Consortium
Indiana University (Indiana University Melvin and Bren Simon Cancer Center) Northwestern University (Robert H. Lurie Comprehensive Cancer Center) Penn State University (Penn State Hershey Cancer Institute) Purdue University (Purdue University Center for Cancer Research) Rutgers University (The...
Big Ten Universities Join Together in Cancer Research Consortium
Leaders from cancer centers affiliated with the “Big Ten” universities joined together in launching the Big Ten Cancer Research Consortium on June 1 in Chicago. The group is uniting to transform cancer research through collaborative oncology trials that leverage the scientific and clinical...
Newly Approved Drugs and Indications
FDA has approved the following new drugs and/or indications in 2013: Denosumab (Xgeva subcutaneous injection) for giant cell tumor of bone. Lenalidomide (Revlimid capsules) for relapsed/refractory mantle cell lymphoma FDA approved. Trametinib (Mekinist tablets) for unresectable or metastatic...
Gary L. Dillehay, MD, Is New President, Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) recently announced the appointment of Gary L. Dillehay, MD, FACNM, FACR, to 2013-2014 President, SNMMI, during the Society’s Annual Meeting in Vancouver. Dr. Dillehay is Professor of Radiology at Northwestern Memorial Hospital in...
Molecular Imaging Improves Care in Pediatric Glioma
The amino acid imaging agent, O-(2-[18F]-fluoroethyl)-L-tyrosine (F-18 FET), may improve upon standard magnetic resonance imaging (MRI) and its diagnostic benefit for imaging pediatric gliomas when conventional MRI is not sufficient, said researchers at the Society of Nuclear Medicine and Molecular ...
AMA Announces 2013-2014 Board of Trustees; Names Oncologist Barbara McAneny, MD, Chair-elect
The American Medical Association (AMA) recently introduced the 21 members of its Board of Trustees for the coming year following elections held during the Annual Meeting of the AMA House of Delegates. The new Chair of the AMA Board of Trustees is David O. Barbe, MD, MHA, a Family Medicine physician ...
American Geriatrics Society Presents Diane E. Meier, MD, the 2013 Edward Henderson Award
The American Geriatrics Society (AGS) presented Diane E. Meier, MD, the 2013 Edward Henderson Award in recognition of her many invaluable contributions to the field of geriatrics. Dr. Meier received the award and delivered the Henderson State-of-the-Art Lecture during AGS’ Annual Scientific Meeting ...
Oncology Meetings
July WIN 2013 Symposium: Personalized Cancer Therapy: From Innovation to ImplementationJuly 10-12 • Paris, FranceFor more information: www.winsymposium.org 12th International Congress on the Future of Breast CancerJuly 18-20 • Huntington Beach, CaliforniaFor more information:...
Results of AXIS Trial Indicate a Significant Improvement over Historical Survival Data in Renal Cell Carcinoma
The phase III open-label AXIS trial comparing axitinib (Inlyta) vs sorafenib (Nexavar) as second-line treatment for metastatic renal cell carcinoma has shown a significant difference in median progression-free survival (8.3 months in the axitinib group vs 5.7 months in the sorafenib group; hazard...
Progression of Renal Cell Carcinoma Linked to Shifts in Tumor Metabolism
Investigators in The Cancer Genome Atlas (TCGA) Research Network have uncovered a connection between how tumor cells use energy from metabolic processes and the aggressiveness of the most common form of kidney cancer, clear cell renal cell carcinoma. Their findings demonstrate that normal...
FDA Approves Denosumab to Treat Giant Cell Tumor of the Bone
The U.S. Food and Drug Administration (FDA) has expanded the approved use of denosumab (Xgeva) to treat adults and some adolescents with giant cell tumor of the bone, a rare and usually noncancerous tumor. Denosumab, which was granted orphan product designation, was reviewed under the FDA’s...
Investigational New Drug Application Filed for CFI-400945
Investigators from Princess Margaret Cancer Centre in Toronto and the University of California, Los Angeles, have submitted an Investigational New Drug (IND) application for CFI-400945, a novel drug candidate targeting the enzyme PLK4, which plays a crucial role in cell division. The news was...
Immunohistochemistry Effectively Detects ALK Rearrangement in Non-small Cell Lung Cancer Study
ALK rearrangement has been demonstrated to be a potent oncogenic driver and a promising therapeutic target in non-small cell lung cancer. It defines a distinct molecular subset of NSCLC, in particular adenocarcinoma that can benefit by the treatment of ALK-inhibitors. Development of robust and...
ASCO Answers Guides to Breast, Colorectal, Prostate, and Lung Cancer Now Available to Order
The ASCO Answers guides to cancer are designed to help patients newly diagnosed with cancer understand their disease and treatment options. These comprehensive, patient-friendly booklets contain trusted information about diagnosis, treatment, side effects, and the psychosocial effects of cancer....
New International Innovation Grant Directly Supports Research Projects in Developing Countries
The Conquer Cancer Foundation and ASCO International have just launched a new research funding opportunity, the Conquer Cancer Foundation of ASCO International Innovation Grant, which directly supports research being conducted by investigators in low- and middle-income countries. Advancing Cancer...
ASCO Issues Progress Report on Blueprint for Cancer Research
ASCO has released a Progress Report on the gains made toward achieving goals set forth in its landmark 2011 report, Blueprint for Transforming Clinical and Translational Cancer Research. The ASCO Blueprint laid out an innovative roadmap for the clinical research system to capitalize on the new...
Institute Initiatives Help Oncologists Integrate Evidence-based Guidelines in Practice
Building on ASCO’s longstanding commitment to drive quality, value, and accountability in cancer care, the Institute for Quality’s initiatives provide oncologists with resources to ensure that every patient receives the highest level of cancer care. Established in 2011, the Institute for Quality...
Business Summit Fosters Innovative Solutions to Oncology Market Challenges
To provide a forum for key cancer stakeholders to join with business, finance, and legal thought leaders to explore the future course for oncology, ASCO is co-hosting the seventh annual Cancer Center Business Summit on October 24 and 25 in Chicago, Illinois. Designed as a resource for the business...
2013 Breast Cancer Symposium to Offer Expanded Meet the Professor Sessions and New Fellows, Residents, and Junior Faculty Track
As a cancer care specialist, it can be easy to become hyperfocused on your area of expertise within your subspecialty. But that’s exactly what ASCO wants its members—in all specialties—to avoid. The theme of this year’s Breast Cancer Symposium—Multidisciplinary Perspectives on Clinical...
Study Reports 25% of Women Don't Complete Recommended Breast Cancer Treatment
One-quarter of women who should take hormone-blocking therapies as part of their breast cancer treatment either do not start or do not complete the 5-year course, according to a new study led by University of Michigan Comprehensive Cancer Center researchers. For many women with hormone...
Venous Thromboembolism in Patients with Cancer: Real-world Challenges for the Practicing Oncologist
The close association between cancer and thrombosis has been recognized now for more than 150 years.1 Not only is it now known that patients with cancer are at substantially increased risk of developing venous thromboembolism, even prior to the diagnosis of cancer, but the association between...
SIDEBAR: Venous Thromboembolism Expert Panel
Gary H. Lyman, MD, MPH, FRCP (Edin), Co-Chair, Duke University Medical Center Anna Falanga, MD, Co-Chair, Ospedali Riuiniti Bergamo, Italy Daniel Clarke-Pearson, MD, University of North Carolina Christopher Flowers, MD, MS, Winship Cancer Institute Charles W. Francis, MD, University of...
Updated ASCO Clinical Practice Guideline for Venous Thromboembolism Prophylaxis and Treatment
ASCO has released a new evidence-based clinical practice guideline for venous thromboembolism prophylaxis and treatment, updating the 2007 practice guideline.1 The update is based on a systematic review of literature published from December 2007 to December 2012. An Update Committee reviewed...
Expert Point of View: Richard Goldberg, MD
The FIRE-3 investigators did not report the use of salvage treatments, and this may be confounding the results, according to Richard Goldberg, MD, who discussed the paper at an ASCO press briefing. Dr. Goldberg is Professor of Medicine at The Ohio State University, Columbus. “The study shows a...
Best First-line Treatment for Advanced Colorectal Cancer Remains Unclear
In patients with advanced colorectal cancer, it remains unclear which biologic agent added to standard chemotherapy is best, even after a head-to-head comparison of two commonly used agents. In the phase III FIRE-3 trial, conducted by the German AIO CRC Study Group, the addition of cetuximab...
Two New Genetic Tests Offer Progress in Personalized Medicine for Newly Diagnosed Prostate Cancer
At least 12 different genetic tests for prostate cancer are under development. The two tests currently available are Oncotype DX (Genomic Health, Redwood City, California) and Prolaris (Myriad Genetic Laboratories, Salt Lake City). Both tests can identify which low-risk patients are “truly” at low...
Benefit for Dual HER2 Targeting in Neoadjuvant Breast Cancer Regimen Restricted to Subset of Patients
As a neoadjuvant regimen for HER2-positive early breast cancer, the use of two HER2-directed agents was no more effective than trastuzumab (Herceptin) alone in producing pathologic complete responses, although one subset of patients did benefit from this approach, according to the results of the...
ASCO Impact Report Indicates Strong Interest in New Treatments for Melanoma and Cervical Cancer
New treatments for melanoma and cervical cancer were cited as the most important subjects of new clinical information presented at the 2013 ASCO Annual Meerting, according to the second annual ASCO Impact Report released recently by Encuity Research. New treatments for melanoma, with an emphasis...
Search for Biomarkers of mTOR Inhibitor Benefit in Breast Cancer Fails to Pan Out
The search for a biomarker of benefit from mTOR inhibitors in breast cancer fell flat in an exploratory genetic analysis of the BOLERO-2 trial, presented at the 2013 ASCO Annual Meeting by Gabriel N. Hortobagyi, MD, FACP, Professor of Breast Medical Oncology at The University of Texas MD Anderson...
ASCO Will Change with the Times
At the 2013 ASCO Annual Meeting, The ASCO Post caught up with new President Clifford A. Hudis, MD, Chief of the Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center, New York, for a glimpse of his plans for ASCO in the coming year, and his thoughts on being elected ASCO...
Idelalisib, Obinutuzumab Show Encouraging Results in CLL Studies
A trio of presentations at the ASCO Annual Meeting focused on two promising investigational drugs for the treatment of chronic lymphocytic leukemia (CLL). These two drugs—idelalisib and obinutuzumab—join a list of new approaches showing potential. Idelalisib Alone A phase I dose-ranging study of...
First Positive Trial of Heat Shock Protein 90 Inhibitor in Lung Cancer That Has Progressed after First-line Therapy
The investigational heat shock protein (Hsp)90 inhibitor ganetespib plus docetaxel extended overall survival compared with docetaxel alone as second-line therapy in patients with advanced non–small cell adenocarcinoma of the lung that had progressed on first-line therapy in the randomized phase II...
Second-generation ALK Inhibitor Breakthrough Drug Promising in Early Study for Non–Small Cell Lung Cancer
Encouraging results were seen in a preliminary study of a second-generation ALK inhibitor in advanced ALK-positive non–small cell lung cancer (NSCLC). The drug—dubbed LDK378—achieved tumor shrinkage in almost all patients enrolled in the study, in all mutational subsets, in crizotinib...
SIDEBAR: More on Palliative Care from Selma Schimmel
At the 2013 ASCO Annual Meeting, Selma Schimmel conducted a series of interviews with prominent oncologists, to get their perspectives on palliative care. These discussions can be viewed via The Group Room website here: http://thegrouproom.tv/category/cancer-topics/palliative-care/ All Vital...
Despite a Recurrence, I'm Not Surrendering My Life to Cancer
This is the first time I’m going public with the fact that I have advanced ovarian cancer. I thought I could avoid the fate of my mother and her mother, both of whom died of ovarian cancer in their 50s, and live well past my 60s and even 70s. But at 58, I’ve had to accept that that is not likely. I ...
Bevacizumab in Glioblastoma: Another Perspective
Given the results of the AVAglio trial, we feel that a more balanced discussion about the role of bevacizumab (Avastin) in patients with newly diagnosed glioblastoma is in order. The accompanying article in The ASCO Post suggests that bevacizumab has no benefit in newly diagnosed glioblastoma; data ...
